Cryo-Save Group N.V. (AIM: CRYO, “Cryo-Save” or “the Company”), Europe’s leading stem cell bank, confirms that pursuant to the passing of the relevant resolutions at an EGM of the Company held on 5 October 2009, and as notified on that day, the proposed 5:1 share consolidation has this morning become effective.
As result of the share consolidation the Company’s authorised share capital now comprises 9,639,191 ordinary shares of €0.10 each; the associated depository interests for these ordinary shares will commence trading at 8:00 am today under ISIN NL0009272137.
For further details:
Cryo-Save Group +31 (0) 575 548 998
Marc Waeterschoot, Chief Executive
Arnoud van Tulder, Chief Financial Officer
Daniel Stewart & Company plc +44 (0) 20 7776 6550
Simon Leathers
College Hill +44 (0) 20 7457 2020
Adrian Duffield/Rozi Morris